Buprenorphine Update: Practical Applications & State of the Art Innovations in OBOT

Primary care clinicians, mental health and addiction treatment providers who prescribe buprenorphine are faced with the unique clinical challenge of providing daily doses of an opioid to patients with addictive disease. 1. There are challenging clinical issues involved: stabilization v. maintenance doses; treating opiate addicted patients who have concomitant chronic intractable pain; treating opiate addicted patients with co-morbid depressive or anxiety disorders or sleep disturbances; and management of opiate medication side-effects are just a few examples. 2. There are unique ethical issues involved: patient safety v. minimization of disruption to patient daily life and the obligation to the individual patient v. the obligation to the community well-being. 3. There are unique Patient-Doctor and Patient-Treatment Program issues: staff splitting by patients; appropriately supervising toxicology testing while maintaining dignity; patient confidentiality concerns v. the need to have data from other providers regarding patient stability; and issues about dose adjustment, level of supervision and documentation. 4. There are rapidly changing expectations and concerns from regulatory agencies that must be understood and integrated into an evolving standard of care, and documented during increasingly frequent site visits and chart audits. It is for these reasons that faculty from the CWRU School of Medicine Addiction Psychiatry and Addiction Medicine Fellowship Programs has developed this special buprenorphine update.

Wednesday, May 3, 2023, 7:50 AM - 4:45 PM, VIRTUAL

1. Describe the pharmacologic profiles of buprenorphine, other opioids, benzodiazepines, THC and psychostimulants with regards to their interaction with the addiction prone brain
2. Identify approaches to effectively address anxiety / depression / chronic pain / insomnia in the context of OBOT
3. Employ techniques relating to minimizing the diversion of buprenorphine including use of different delivery systems
4. Discuss risk management, office documentation and best practice guidelines for buprenorphine prescribing as well as evolving and emerging State and Federal requirements
5. Practice difficult conversations when maintaining boundaries and clinical expectations in the OBOT clinic
6. Compare and contrast “harm reduction” with “adjunct to sobriety” OBOT treatment approaches

The registration fee for this course is $200.

An administrative fee of $50 will be deducted from refunds for cancellations made within 14 days of the course.  All requests for refunds must be sent via email to [email protected].

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (8.00 hours), Non-Physician Attendance (8.00 hours)

You are not logged in.

Please click the button below to login or create a new account before continuing.

Wednesday, May 3, 2023